Intravitreal bevacizumab for inflammatory choroidal neovascularization: Results from the Pan-American collaborative retina study group at 24 months

Retina

Volumn 31, Issue 2, 2011, Pages 353-363

  Arevalo, J Fernando ^a   Adan, Alfredo ^b   Berrocal, Maria H ^c   Espinoza, Juan V ^a   Maia, Mauricio ^d   Wu, Lihteh ^e   Roca, Jose A ^f   Quiroz Mercado, Hugo ^g   Ruiz Moreno, Jose M ^h   Serrano, Martin A ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e Instituto de Cirugia Ocular   (Costa Rica)

^f CLÍNICA RICARDO PALMA   (Peru)

^g HOSPITAL DR LUIS SÁNCHEZ BULNES   (Mexico)

^h Alicante   (Spain)

Author keywords

Avastin; bevacizumab; choroidal neovascularization; CNV; inflammatory; intravitreal injections

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CHORIORETINAL INFLAMMATORY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFLAMMATORY CHOROIDAL NEOVASCULARIZATION; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; RETINITIS; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS, POSTERIOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 79551508522     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ed8cec     Document Type: Article

References (31)

1. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143: 977-983.
2. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004;137:496-503.
3. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241-1244.
4. Chan WM, Lai T, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: One-year results of a prospective series. Retina 2008;28:71-80.
5. Quillen DA, Davis JB, Gottlieb JL, et al. The white dot syndromes. Am J Ophthalmol 2004;137:538-550.
6. Ho AC, Yannuzzi LA, Pisicano K, DeRosa J. The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology 1995;102:1411-1412.
7. Gass JDM. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994; 118:285-298.
8. Lafaut BA, Aisenbrey S, Vanden Broecke C, Bartz-Schmidt KU. Clinicopathological correlation in exudative age related macular degeneration: Histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 2000;84:239-243.
9. Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-1186.
10. Macular Photocoagulation Study Group. Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol 1983;101: 1358-1361.
11. Lit ES, Kim RY, Damico DJ. Surgical removal of subfoveal choroidal neovascularization without removal of posterior hyaloid: A consecutive series in younger patients. Retina 2001; 21:317-323.
12. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508.
13. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158-3164.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
15. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Pan- American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-750.
16. Maturi RK, Bleau LA,Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
17. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
18. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140: 509-516.
19. Tatar O, Yoeuek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126:782-790.
20. Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 2003;241:899-906.
21. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2009;148:310-316.
22. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008;146:410-416.
23. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 2009;29: 8-12.
24. Schadlu R, Blinder JK, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008;145:875-878.
25. Adan A, Navarro M, Casaroli-Marano RP, Ortiz S, Molina JJ. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 2007; 245:1873-1875.
26. Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol 2008;28:311-316.
27. Wu L, Evans T, Saravia M, Schlaen A, Couto C. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 2009;53: 57-60.
28. Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008;246:1685-1692.
29. Chang LK, Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945.
30. Doctor PP, Bhat P, Sayed R, Foster CS. Intravitreal bevacizumab for uveitic choroidal neovascularization. Ocul Immunol Inflamm 2009;17:118-126.
31. Kramer M, Axer-Siegel R, Jaouni T, et al. Bevacizumab for choroidal neovascularization related to inflammatory diseases. Retina 2010;30:938-944.